Literature DB >> 3449093

Synthesis, chemical stability and pre-clinical anti-tumor activity of pyrazine diazohydroxide, sodium salt (NSC-361456).

D C Baker1, E S Hand, J Plowman, J B Rampal, A Safavy, R D Haugwitz, V L Narayanan.   

Abstract

The synthesis, chemical stability and anti-tumor activity of pyrazine diazohydroxide, sodium salt, a compound that has been selected for development to clinical trials, are described. The compound shows a half-life of about 100 minutes at pH 7.4 and is active against a number of experimental tumors.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3449093

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN： 0266-9536


  4 in total

1.  Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.

Authors:  S D Harrison; J Plowman; D J Dykes; W R Waud; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.

Authors:  M V Dhodapkar; R L Richardson; J M Reid; M M Ames
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

3.  Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro.

Authors:  D L Du; D A Volpe; C K Grieshaber; M J Murphy
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

4.  A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.

Authors:  Robert P Whitehead; Joseph M Unger; Lawrence E Flaherty; Eric H Kraut; Glenn M Mills; Catherine E Klein; Robert A Chapman; Gary C Doolittle; Neel Hammond; Vernon K Sondak
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.651
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.